Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
In this phase 2 single-arm clinical trial, 30 patients with HER2-positive metastatic breast
cancer after progression on trastuzumab are enrolled and receive treatment of Inetetamab plus
Pyrotinib plus Oral Vinorelbine. The study aimed to access the efficacy and safety of
Inetetamab combined with Pyrotinib and Oral Vinorelbine in HER2-positive metastatic breast
cancer patients after progression on trastuzumab.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University